Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Szazhalombatta – page 71

1 121 clinical trials in Szazhalombatta, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Szazhalombatta at a glance
1 121
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 121 trials in Szazhalombatta

Open in trial search

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astrazeneca AB

Asthma

Not recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Areteia Therapeutics Inc.

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Astrazeneca AB

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Acalabrutinib and Venetoclax with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Astrazeneca AB

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Astrazeneca AB

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astrazeneca AB

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Alkylating agents
  • Sponsor:Geron Corp.

Asthma

Not recruiting

Study on the Effectiveness and Safety of Fluticasone Propionate and Salbutamol Sulfate for Patients with Asthma

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Szazhalombatta

What the registry says about research in the country

01 Respiratory Disease Management

Innovative clinical research focusing on moderate-to-severe asthma, evaluating new therapeutic approaches including dupilumab and amlitelimab for improved lung function and symptom control.

  • Long-term lung function preservation
  • Novel therapeutic evaluation
  • Disease control optimization

Multiple trials are exploring preventive strategies and treatment effectiveness in asthma management.

02 COPD Treatment Innovation

Comprehensive studies examining chronic obstructive pulmonary disease treatments, including evaluation of triple therapy combinations and novel biological agents.

  • Exacerbation reduction strategies
  • Cardiopulmonary outcomes
  • Advanced therapeutic combinations

Research focuses on improving quality of life and reducing disease progression in COPD patients.

03 Advanced Respiratory Therapeutics

Investigation of innovative biological treatments for both asthma and COPD, including studies of benralizumab and itepekimab for patients with severe symptoms.

  • Long-term safety assessment
  • Targeted biological therapies
  • Patient response monitoring

These trials aim to establish new standards in respiratory disease treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.